Growth arrest are that TORC1 inhibition only in cell lines and BCR 786O A498.86 In contrast, T ACTION in models of breast cancer was only observed in cell lines with HER2 amplification and WZ4002 / or PIK3CA mutation.87 with Phase I data for the NVP BEZ235 in advanced solid tumors recently reported, k these observations can be used to guide further clinical development of agent.88 By signing the American Recovery and Reinvestment Act in the year 2009, there is now an important impetus to carry out comparative effectiveness research.89 the oncology community must, therefore, in selecting the most promising inhibitors of Akt manage in studies that focus on existing standards. Since these studies are organized fa Is appropriate for big s Phase III trial, it will have the discretion as Akt inhibitors are reported.
With strategies of biomarkers in this report m Allow legally possible to identify that unique populations benefit from this class of agents. Validation of a biomarker to E7080 VEGFR inhibitor predict response would lead to future studies with a smaller population, saving resources for clinical trials in patients with negative markers that may have a suboptimal response. Although Akt inhibitors are promising, the challenge before us, their incorporation into treatment algorithms malignancies. important to determine whether activation of Akt phosphorylation, or can / mutation in combination with other mediators to predict the effectiveness of this class of agents. 5.1.1 Akt phosphorylation above mentioned HNT, Phosphorylation of critical residues in the results of the migration of Akt in the fraction of the cell membrane and subsequently Activation by PDK1 depends Have ngigen processes.
7 Several studies suggested that measurement of the phosphorylation Akt is associated with clinical outcomes. A study in myeloid leukemia Chemistry Acute suggested that the phosphorylation of Akt at Thr308 indicates a poorer prognosis.53 addition to his R Forecast, k CX-4945 Akt phosphorylation can predict the effectiveness of specific targeted agents. For example, a phase II trial of gefitinib 106 patients with advanced NSCLC who proposed to standard therapy.50 correlative studies suggest that increased hte phosphorylated Akt base an hour here return rate, the rate predicted was advanced evaluation team of professionals of the disease , and time to progression.
In contrast to phosphorylated MAPK levels pAkt had no effect on clinical outcomes. Using these studies as a paradigm, it will be important to see whether the activity t of inhibitors of Akt can be predicted by baseline pAkt. 5.1.2 Modulation of mediators obtained Ltlichen transducer relevant Akt signaling activity, the t’s of inhibitors of PI3K act directly on the act and locate and gain offunction PIK3CA mutations in the gene have been described in breast, ovarian and colorectal cancer. 73 Although the agents are made to selectively on cells mutated PIK3CA, mutations in the k nnten as biomarkers for response to an act therapies.74 LED, 75 This hypothesis is supported by in vitro experiments with lines of thyroid cancer are supported Cell in cells with mutations in PIK3CA, sensitivity was blunted compared with perifosine 0.76 Statute of the tumor suppressor PTEN can also advance, which may be old act in response to inhibitors of the function of PTEN